BSE · 540729
Vanta Bioscience Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2 Cr with net profit ₹-5 Cr — a -230.19% net margin, versus -23.56% the period before.
Shareholding
As of 2026-09-30
- Promoter72.81%
- Public27.19%
426 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.97× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Miscellaneous · ranked #363 of 552 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| National Stock Exchange Of India Ltd. | ₹4,42,765 Cr | 49.53 | 13.79 | 22.8% | 64.54% |
| Adani Ports & Special Economic Zone Ltd. | ₹4,31,301 Cr | 31.19 | 4.17 | 13.33% | 31.98% |
| Eternal Limited | ₹3,26,037 Cr | 662.45 | 10.41 | 1.58% | 0.63% |
| BSE Limited | ₹1,42,841 Cr | 50.45 | 21.41 | 37.42% | 52.03% |
| Vedanta Aluminium Metal Limited | ₹1,36,453 Cr | 11.36 | 5.92 | 80.07% | 23.43% |
| GAIL (India) Ltd. | ₹1,08,601 Cr | 11 | 1.22 | 8.51% | 6.67% |
| One 97 Communications Ltd. | ₹1,08,337 Cr | 129.23 | 6.53 | 5.15% | 8.95% |
| Meesho Limited | ₹1,04,040 Cr | — | 24.72 | -21.93% | -6.19% |
| GMR Airports Limited | ₹93,038 Cr | 155.84 | 0 | -25.64% | 3.13% |
| Multi Commodity Exchange of India Ltd. | ₹82,388 Cr | 53.44 | 28.91 | 46.75% | 58.61% |
| Vanta Bioscience Limited(this company) | ₹15 Cr | 136 | 0.69 | 0.51% | -113.62% |
AI analysis
AI-generated · google/gemini-2.5-flashVanta Bioscience Limited is listed with a market capitalization of Rs 18 Cr. The company reported revenue of Rs 2.07 Cr and a negative profit margin of 0%. The price to earnings ratio stands at 168.6, with an EPS of Rs 0.15.
Positives
- +Promoter shareholding is 72.81% as of March 2026, indicating significant control.
- +No promoter shares are reported as pledged.
Negatives
- −The company reported a negative profit margin of 0%.
- −Debt-to-equity ratio is high at 5.11, indicating substantial leverage.
- −Revenue decreased from Rs 9.83 Cr in March 2024 to Rs 2.07 Cr in March 2025.
- −Net profit has been negative for the past four reported annual periods, reaching -Rs 4.77 Cr in March 2025.
- −The company is under ESM 1 surveillance.
Financial Performance
Vanta Bioscience Limited's revenue for the fiscal year ending March 2025 was Rs 2.07 Cr. This marks a decrease from Rs 9.83 Cr in March 2024. The company reported a net profit of -Rs 4.77 Cr for the same period, compared to -Rs 2.32 Cr in March 2024. The EPS for March 2025 was -Rs 7.56.
Profitability & Returns
The company's profitability as measured by profit margin was 0%. Return on equity (ROE) was 51.1% and return on capital employed (ROCE) was 1.31%. Earnings per share (EPS) for the latest period was Rs 0.15. The EBITDA for March 2025 was -Rs 8.56 Cr.
Balance Sheet
The debt-to-equity ratio for Vanta Bioscience Limited is 5.11, indicating a high level of debt relative to equity. The book value per share stands at Rs 29.77.
Ownership & Pledges
As of March 31, 2026, the promoter holding in Vanta Bioscience Limited was 72.81%. Public shareholding was 27.19%. There was no reported pledge of promoter shares. There were 426 shareholders in March 2026.
Regulatory & Surveillance
Vanta Bioscience Limited is under ESM (Enhanced Surveillance Measure) Stage 1, indicating increased scrutiny from the exchanges. This measure typically involves additional reporting and trading restrictions.
Data as of — price: 2026-10-30 · financials: Mar 25 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.